Dr Giannis Mountzios speaks to ecancer about the patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients with previously treated small cell lung cancer (SCLC).

In this trial, tarlatamab, a first-in-class DLL3-targeting bispecific T-cell engager, significantly improved patient-reported outcomes compared with chemotherapy in previously treated small cell lung cancer.

Dr Mountzios says that patients receiving tarlatamab experienced better control of key SCLC symptoms including dyspnea, cough, and chest pain, as well as improved physical functioning and global health status.

Tarlatamab also delayed symptom deterioration and caused fewer treatment-related side effects, reinforcing its role as a new standard of care for relapsed SCLC.